Clinical Trial Update: Nephroprotective Effects of Carnitine and (PDE5) Inhibitor Agent Against Contrast Media-induced Nephropathy (CMN) [NA]

View source ↗

Summary

A clinical trial is evaluating whether combining carnitine with a PDE5 inhibitor may protect the kidneys from contrast media-induced nephropathy; the sponsor is…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Contrast-induced Nephropathy

Drugs mentioned

• L-carnitine (L-carnitine)
• PDE5 inhibitor (unspecified)

Snippet

Sponsor: The Nazareth Hospital | Conditions: Contrast Media Induced Nephropathy | NA | Status: UNKNOWN